RS Research — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

RS Research is a clinical-stage biotech leveraging its proprietary Sagitta® targeted delivery platform to develop next-generation polymer-drug conjugates for oncology. The company has a lead candidate, RS-0139 (docetaxel conjugate), currently in Phase I trials, with initial data accepted for presentation at ASCO 2025. Founded by award-winning innovators and recognized as a translational success story, RS Research aims to create safer, more effective chemotherapies and theranostics by selectively delivering payloads to tumors.

Oncology

Technology Platform

Sagitta® platform: a clinically-validated, modular polymer-drug conjugate (PDC) system for targeted delivery. It uses tunable linkers and targeting ligands (e.g., to integrins) to selectively deliver cytotoxic or radiolabeled payloads to tumors, aiming to improve therapeutic index.

Opportunities

The Sagitta® platform could significantly expand the use of existing chemotherapies by improving their safety profile, addressing a massive unmet need in oncology.

Its extension into theranostics (combined diagnosis and therapy) opens an additional, high-growth segment within precision medicine.

Risk Factors

The company faces high clinical risk, as its lead candidate's efficacy in later-stage trials is unproven.

As a private, pre-revenue biotech, it is also heavily dependent on securing future funding to continue its expensive clinical development programs.

Competitive Landscape

RS Research competes in the crowded targeted drug delivery space, which includes established modalities like Antibody-Drug Conjugates (ADCs) and other nanomedicine approaches from both large pharma and biotech. Its differentiation lies in its specific polymer-drug conjugate chemistry and targeting approach.

More companies in Drug Delivery & Formulation →More companies in Switzerland →